Ghiath M. Sukhtian, Director, 10% Owner at Outlook Therapeutics, Inc. (OTLK), bought 2,525,252 shares at $0.99 ($2.5M) on 2026-08-12, disclosed to the SEC on 2026-08-14.
Open-market purchase of $2.5M OTLK by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |